2025-04-22 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Report

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company.  Its stock has significantly outperformed the S&P 500 (VOO) over various periods, exhibiting high growth but also increased volatility.  Recent financial performance indicates strong revenue and profitability, though recent price action shows some weakness.


**1. Performance Comparison & Alpha/Beta Analysis:**

LLY's cumulative return (305.29%) drastically exceeds that of the S&P 500 (72.42%), resulting in a significant divergence. The current relative divergence of 71.1%  indicates LLY's performance is considerably higher than the S&P 500 throughout the analyzed period, though past performance is not indicative of future results.


The Alpha/Beta analysis shows consistently positive alpha values across the analyzed periods, indicating that LLY has generated excess returns compared to the market (beta represents the stock's volatility relative to the market). The beta values fluctuate but generally remain high, reflecting LLY's higher volatility.  The market capitalization (Cap(B)) shows consistent and significant growth.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 69.5 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 97.6 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 113.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 148.6 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 246.8 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 331.3 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 533.1 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 710.6 |
| 2023-2025  | 137.0% | 76.8% | 126.0% | 0.2 | 754.3 |


**2. Recent Price Movement:**

* **Closing Price:** $818.02
* **Previous Close:** $839.96
* **Change:** -$21.94 (-2.61%)
* **5-Day Moving Average:** $780.88
* **20-Day Moving Average:** $786.31
* **60-Day Moving Average:** $831.59

The price is below all three moving averages, suggesting a potential short-term downtrend.  The significant drop from the previous close indicates a possible short-term correction.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4082 (Medium Risk)
* **RSI:** 48.95 (Approaching oversold territory, but not yet)
* **PPO:** 0.98 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +3.1% (Short-term upward trend)
* **Expected Return:** 80.0% (This is a high estimate, which should be considered in conjunction with the inherent risks)

The price drop of $21.94 reflects a significant negative change, indicating a potentially sharp correction.  The high expected return is contingent on long-term investment and should be evaluated considering the inherent market volatility and risk.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-10-30 | $1.08   | $11.44 B      |
| 2024-08-08 | $3.29   | $11.30 B      |
| 2024-04-30 | $2.49   | $8.77 B       |
| 2023-11-02 | -$0.06  | $9.50 B       |
| 2024-10-30 | -$0.06  | $9.50 B       | *(Duplicate entry, likely a data error)*

Revenue has been relatively stable, though there's fluctuation in EPS. The negative EPS in two entries require further investigation to determine the cause.  Inconsistency in data needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $13.53B  | 82.24%        |
| 2024-09-30 | $11.44B  | 81.02%        |
| 2024-06-30 | $11.30B  | 80.80%        |
| 2024-03-31 | $8.77B   | 80.91%        |
| 2023-12-31 | $9.35B   | 80.88%        |

Revenue shows a positive trend, with high and relatively stable profit margins.


**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-12-31 | $14.19B  | 31.07%  |
| 2024-09-30 | $14.24B  | 6.81%   |
| 2024-06-30 | $13.56B  | 21.88%  |
| 2024-03-31 | $12.81B  | 17.51%  |
| 2023-12-31 | $10.77B  | 20.33%  |

Equity is generally increasing, however, ROE fluctuates significantly, requiring further analysis to understand the underlying causes of this variation.


**6. Overall Analysis:**

LLY has shown exceptional growth compared to the S&P 500, with high alpha and a strong revenue stream. However, recent price action suggests a potential short-term correction.  The high expected return needs careful consideration, given the inherent volatility of the pharmaceutical industry and the potential impact of regulatory changes or competitive pressures.  Further investigation into inconsistent earnings data and the fluctuating ROE is crucial before making any investment decisions.  A thorough due diligence process, including reviewing the company's financial statements, is recommended before investing.
